Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antibodies, Monoclonal"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 673
Tytuł:
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
Autorzy:
Heine RJSD; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Thielen FW; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Rotterdam, The Netherlands.
van Leeuwen RWF; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Rotterdam, The Netherlands.
Franken MG; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Uyl-de Groot CA; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 01; Vol. 19 (2), pp. e0293264. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Drug Costs*
Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; Cost Control
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Therapeutic Monoclonal Antibodies against Cancer: Present and Future.
Autorzy:
Delgado M; Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), 28040 Madrid, Spain.
Garcia-Sanz JA; Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), 28040 Madrid, Spain.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Dec 14; Vol. 12 (24). Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Neoplasms*/drug therapy
Humans ; Prospective Studies ; Antibodies, Monoclonal, Humanized ; Immunotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
Autorzy:
Shaban N; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.
Kamashev D; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.; Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Emelianova A; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Buzdin A; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Laboratory for Translational Genomic Bioinformatics, Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.; Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.; PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Dec 25; Vol. 13 (1). Date of Electronic Publication: 2023 Dec 25.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*
Neoplasms*/drug therapy
Humans ; Biomarkers ; ErbB Receptors ; Biology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.
Autorzy:
Wang T; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Wang SQ; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Du YX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.
Sun DD; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Liu C; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Liu S; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Sun YY; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Wang HL; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Zhang CS; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Liu HL; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China.
Jin L; GeneScience Pharmaceuticals Co., Ltd, Changchun, 130012, Jilin, People's Republic of China. .
Chen XP; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. .; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Mar 01; Vol. 22 (1), pp. 220. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
CD47 Antigen*
Neoplasms*/pathology
Animals ; Humans ; Phagocytosis ; Macrophages/metabolism ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Immunotherapy/methods ; Disease Models, Animal ; Antigens, Differentiation/metabolism ; Antigens, Differentiation/pharmacology ; Antigens, Differentiation/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody.
Autorzy:
Andersson H; Alligator Bioscience AB, 223 81 Lund, Sweden.; Department of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Sobti A; Alligator Bioscience AB, 223 81 Lund, Sweden.
Jimenez DG; Alligator Bioscience AB, 223 81 Lund, Sweden.
de Coaña YP; Alligator Bioscience AB, 223 81 Lund, Sweden.
Ambarkhane SV; Alligator Bioscience AB, 223 81 Lund, Sweden.
Hägerbrand K; Alligator Bioscience AB, 223 81 Lund, Sweden.
Smith KE; Alligator Bioscience AB, 223 81 Lund, Sweden.
Lindstedt M; Alligator Bioscience AB, 223 81 Lund, Sweden.; Department of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Ellmark P; Alligator Bioscience AB, 223 81 Lund, Sweden.; Department of Immunotechnology, Lund University, 223 81 Lund, Sweden.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Sep 27; Vol. 12 (19). Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Antibodies, Monoclonal, Humanized*/pharmacology
Antibodies, Monoclonal, Humanized*/therapeutic use
CD8-Positive T-Lymphocytes*
Neoplasms*/drug therapy
Humans ; CD40 Antigens/immunology ; Sequence Analysis, RNA
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Autorzy:
Yu T; BeiGene USA, Inc., San Mateo, California, USA.
Liu X; BeiGene USA, Inc., San Mateo, California, USA.
Wu CY; BeiGene USA, Inc., San Mateo, California, USA.
Tang Z; BeiGene USA, Inc., San Mateo, California, USA.
Wang H; BeiGene USA, Inc., Cambridge, Massachusetts, USA.
Schnell P; BeiGene USA, Inc., Ridgefield Park, New Jersey, USA.
Wan Y; BeiGene (Shanghai) Co., Ltd., Shanghai, China.
Wang K; Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
Liu L; Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
Gao Y; Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
Sahasranaman S; BeiGene USA, Inc., San Mateo, California, USA.
Budha N; BeiGene USA, Inc., San Mateo, California, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13769.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/pathology
Hematologic Neoplasms*
Drug-Related Side Effects and Adverse Reactions*
Humans ; Antibodies, Monoclonal, Humanized/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Generation of epitope-specific hCG aptamers through a novel targeted selection approach.
Autorzy:
Ferreira L; Biotechnology Innovation Centre, Rhodes University, Grahamstown, Eastern Cape, South Africa.
Flanagan SP; Biotechnology Innovation Centre, Rhodes University, Grahamstown, Eastern Cape, South Africa.
Fogel R; Biotechnology Innovation Centre, Rhodes University, Grahamstown, Eastern Cape, South Africa.
Limson JL; Biotechnology Innovation Centre, Rhodes University, Grahamstown, Eastern Cape, South Africa.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 23; Vol. 19 (2), pp. e0295673. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Chorionic Gonadotropin, beta Subunit, Human*
Neoplasms*
Pregnancy ; Female ; Humans ; Epitopes ; Chorionic Gonadotropin/metabolism ; Peptide Fragments ; Immunoassay ; Antibodies, Monoclonal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
Autorzy:
Mohammadi KA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Brackin T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Schwartz GG; University of Colorado School of Medicine, Aurora, Colorado, USA.
Steg PG; Université Paris-Cité, Paris, France.; FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
Szarek M; State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.; CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Pordy R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Fazio S; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 16859-16868. Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Neoplasms*/epidemiology
Neoplasms*/drug therapy
PCSK9 Inhibitors*/adverse effects
PCSK9 Inhibitors*/therapeutic use
Humans ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Risk Assessment ; Subtilisins ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Novel Anti-CD44 Variant 3 Monoclonal Antibody C 44 Mab-6 Was Established for Multiple Applications.
Autorzy:
Suzuki H; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Kitamura K; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Goto N; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Ishikawa K; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Ouchida T; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Tanaka T; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Kaneko MK; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Kato Y; Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 07; Vol. 24 (9). Date of Electronic Publication: 2023 May 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Neoplasms*
Animals ; Cricetinae ; Humans ; CHO Cells ; Cricetulus ; Immunohistochemistry ; Protein Isoforms/genetics ; Hyaluronan Receptors/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of Chelator-to-Antibody Ratio on Development of Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor.
Autorzy:
Tsai SC; Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
Farn SS; National Atomic Research Institute, Taoyuan 325207, Taiwan.
Lo WL; National Atomic Research Institute, Taoyuan 325207, Taiwan.
Ou Yang FY; National Atomic Research Institute, Taoyuan 325207, Taiwan.
Kang YC; Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 406053, Taiwan.
Chen LC; National Atomic Research Institute, Taoyuan 325207, Taiwan.
Chen KT; Department of Chemistry, National Dong Hwa University, Hualien 974301, Taiwan.
Liao JW; Graduate Institute of Veterinary Pathobiology, National Chung-Hsing University, Taichung 402202, Taiwan.
Kung JY; Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
Chen JT; National Atomic Research Institute, Taoyuan 325207, Taiwan.
Huang FJ; Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 406053, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 05; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 05.
Typ publikacji:
Journal Article
MeSH Terms:
Chelating Agents*/therapeutic use
Neoplasms*/drug therapy
Humans ; Mice ; Animals ; Radioisotopes/therapeutic use ; Positron-Emission Tomography/methods ; Antibodies, Monoclonal/therapeutic use ; Tissue Distribution ; B7-H1 Antigen ; Deferoxamine/therapeutic use ; Zirconium/pharmacokinetics ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Selection, characterization and in vivo evaluation of novel CD44v6-targeting antibodies for targeted molecular radiotherapy.
Autorzy:
Mortensen ACL; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. .; Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden. .
Berglund H; Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden.
Segerström L; Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden.
Walle M; Drug Discovery and Development Platform, Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.; Department of Immunotechnology, Lund University, Lund, Sweden.
Hofström C; Drug Discovery and Development Platform, Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.; Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Persson H; Drug Discovery and Development Platform, Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.; Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Nygren PÅ; Drug Discovery and Development Platform, Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.; Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Nilvebrant J; Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Frejd FY; Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden.
Nestor M; Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 24; Vol. 13 (1), pp. 20648. Date of Electronic Publication: 2023 Nov 24.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/pathology
Humans ; Animals ; Mice ; Tissue Distribution ; Antibodies, Monoclonal/metabolism ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
Autorzy:
Zhang L; Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences, Beijing, China.
Zhao X; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Niu Y; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ma X; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan W; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ma J; Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences, Beijing, China.
Pokaż więcej
Źródło:
Journal of extracellular vesicles [J Extracell Vesicles] 2023 Nov; Vol. 12 (11), pp. e12379.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Extracellular Vesicles*/metabolism
Neoplasms*/pathology
Humans ; CD47 Antigen/metabolism ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor/therapeutic use ; Immunotherapy ; Antibodies, Monoclonal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Radioiodination, purification, and evaluation of antihuman tumor-derived immunoglobulin G light chain monoclonal antibody in tumor-bearing nude mice.
Autorzy:
Sun H; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Yan P; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Wang R; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.; Department of Nuclear Medicine, Peking University International Hospital, Beijing, China.
Du Y; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Zhang C; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Guo F; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Kang L; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Cui Y; Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Pokaż więcej
Źródło:
Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2023 Mar; Vol. 66 (3), pp. 108-115. Date of Electronic Publication: 2023 Mar 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*
Neoplasms*
Animals ; Mice ; Humans ; Mice, Nude ; Iodine Radioisotopes ; Immunoglobulin Light Chains/metabolism ; Immunoglobulin G ; Tissue Distribution ; Prospective Studies ; Tomography, Emission-Computed, Single-Photon/methods ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors].
Autorzy:
Liu RR; Department of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
Gu SZ; Department of Interventional Radiology, Hunan Cancer Hospital, Changsha 410031, China.
Zhou T; Department of Urology, Changhai Hospital of Shanghai, Shanghai 200433, China.
Lin LZ; Cancer Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Chen WC; Department of Gastroenterology, First Affiliated Hospital to Soochow University, Suzhou 215006, China.
Zhong DS; Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Liu TS; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yang N; Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha 410031, China.
Shen L; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing 100142, China.
Xu SY; 3D Medicines Co. Ltd, Chengdu 610036, China.
Lu N; 3D Medicines Co. Ltd, Chengdu 610036, China.
Zhang Y; 3D Medicines Co. Ltd, Chengdu 610036, China.
Gong ZL; 3D Medicines Co. Ltd, Chengdu 610036, China.
Xu JM; Department of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Oct 23; Vol. 45 (10), pp. 898-903.
Typ publikacji:
Clinical Trial, Phase I; Multicenter Study; English Abstract; Journal Article
MeSH Terms:
East Asian People*
Neoplasms*/drug therapy
Neoplasms*/pathology
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.
Autorzy:
Peng SH; Department of Oncology, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
Lin CH; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Chen IC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Shen YC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Chang DY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Chen TW; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Huang SM; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Hu FC; Graduate Institute of Clinical Medicine and School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan.; Statistical Consulting Clinic, International-Harvard (I-H) Statistical Consulting Company, Taipei, Taiwan.
Lu YS; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 20035-20051. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:
Systematic Review; Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Survival Analysis ; Proportional Hazards Models ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
mAb-Functionalized Biomimetic MamC-Mediated-Magnetoliposomes as Drug Delivery Systems for Cancer Therapy.
Autorzy:
Oltolina F; Department of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.; Dipartimento di Scienze della Salute, Università del Piemonte Orientale 'A. Avogadro', Via Solaroli 17, 28100 Novara, Italy.
Santaella Escolano MDC; Department of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.
Jabalera Y; Department of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.
Prat M; Dipartimento di Scienze della Salute, Università del Piemonte Orientale 'A. Avogadro', Via Solaroli 17, 28100 Novara, Italy.
Jimenez Lopez C; Department of Microbiology, Faculty of Sciences, University of Granada, 18071 Granada, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 11; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 11.
Typ publikacji:
Journal Article
MeSH Terms:
Biomimetics*
Neoplasms*/drug therapy
Humans ; Drug Delivery Systems ; Antibodies, Monoclonal/pharmacology ; Drug Carriers ; Biological Transport ; Doxorubicin/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Autorzy:
Cai L; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Li Y; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Tan J; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Xu L; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China. .; Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, 510632, China. .
Li Y; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China. .; Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, 510632, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Sep 05; Vol. 16 (1), pp. 101. Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis A Virus Cellular Receptor 2*
Neoplasms*
Humans ; Immunotherapy ; Receptors, Immunologic ; Immune Checkpoint Proteins ; Antibodies, Monoclonal ; Immune Checkpoint Inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review.
Autorzy:
Kaczmarek M; Department of Medical Biotechnology, Poznan University of Medical Sciences, 61-866 Poznań, Poland.; Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Center, 61-866 Poznań, Poland.
Poznańska J; Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
Fechner F; Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
Michalska N; Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
Paszkowska S; Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
Napierała A; Scientific Society of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.
Mackiewicz A; Department of Medical Biotechnology, Poznan University of Medical Sciences, 61-866 Poznań, Poland.; Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Center, 61-866 Poznań, Poland.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Aug 28; Vol. 12 (17). Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cancer Vaccines*/therapeutic use
Neoplasms*/therapy
Humans ; Immunotherapy ; Adjuvants, Immunologic ; Adjuvants, Pharmaceutic ; Antibodies, Monoclonal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants.
Autorzy:
Torices L; Biobizkaia Health Research Institute, Barakaldo, Spain.
Nunes-Xavier CE; Biobizkaia Health Research Institute, Barakaldo, Spain.; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
López JI; Biobizkaia Health Research Institute, Barakaldo, Spain.
Pulido R; Biobizkaia Health Research Institute, Barakaldo, Spain.; Ikerbasque, The Basque Foundation for Science, Bilbao, Spain.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Aug 01; Vol. 18 (8), pp. e0289369. Date of Electronic Publication: 2023 Aug 01 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Codon, Nonsense*
Neoplasms*
Humans ; C2 Domains ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Germ-Line Mutation ; Epitopes ; Antibodies, Monoclonal/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 673

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies